Xap Therapeutics use of freshly isolated platelets

• Research type

  Research Study

• Full title

  The use of freshly isolated human platelets for use as a standard (positive control) in in vitro cell-based assays for structural biomarkers (located on cell surface, in cytoplasm or in granules) and platelet activation tests (aggregation, clotting)

• IRAS ID

  305205

• Contact name

  Laurent Jespers

• Contact email

  laurent.jespers@xaptherapeutics.com

• Sponsor organisation

  Xap Therapeutics LTD

• Duration of Study in the UK

  3 years, 0 months, 0 days

• Research summary

  This project aims to study the differentiation of megakaryocytes and subsequent fragmentation into platelets (1-4 weeks culture time). The performance and outcomes of this differentiation process must be evaluated against blood-derived human platelets (positive control). Human platelets cannot be stored or cultured, hence regular access to fresh platelets is required to conduct this project. They will be used as a standard (positive control) in in vitro cell-based assays for structural biomarkers (located on cell surface, in cytoplasm or in granules) and platelet activation tests (aggregation, clotting)

• REC name

  London - Brighton & Sussex Research Ethics Committee

• REC reference

  22/PR/0325

• Date of REC Opinion

  1 Jun 2022

• REC opinion

  Further Information Favourable Opinion